Effects of energy deprivation induced by fluorocitrate in immortalised rat brain microvessel endothelial cells.
The effects of the mitochondrial aconitase inhibitor, fluorocitrate on the immortalised rat brain endothelial cell line (RBE4) were investigated. Treatment with different concentrations of fluorocitrate (0-1 mM) for 24 h induced a significant, concentration-dependent decrease in the MTT reduction (an index of mitochondrial function), intracellular ATP content, glucose consumption and lactate production by RBE4 cell monolayers but did not alter the glucose to lactate ratio at concentrations lower than 0.5 mM. At all concentrations, fluorocitrate induced a significant decrease in the protein content per well. Fluorocitrate treatment of confluent RBE4 cells induced a marked redistribution of the F-actin cytoskeleton from a characteristic marginal band to a more diffuse cytosolic pattern. This redistribution of the cytoskeleton coincided with a reduction in the total cellular F-actin content of the RBE4 cells at fluorocitrate concentrations greater than 0.5 mM. Treatment of confluent RBE4 cells with fluorocitrate had no significant effect on RBE4 cell monolayer permeability measured by FITC-dextran or [14C]sucrose. These results show that whilst energy deprivation following fluorocitrate treatment induces significant changes in the RBE4 cell F-actin cytoskeleton and cellular metabolism, it does not have any significant effect on endothelial cell monolayer permeability. These results demonstrate that profound toxic effects on endothelial cell structure and metabolism are not necessarily accompanied by changes in endothelial cell monolayer permeability.
Rist
R J
RJ
Biomedical Sciences Division, King's College London, Strand, UK.
Romero
I A
IA
Chan
M W
MW
Abbott
N J
NJ
D000199:Actins / Q000378:metabolism; D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D002199:Capillary Permeability / Q000187:drug effects; D002461:Cell Line, Transformed; D002560:Cerebrovascular Circulation; D002951:Citrates / Q000494:pharmacology*; D003599:Cytoskeleton / Q000378:metabolism / Q000648:ultrastructure; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism*; D004734:Energy Metabolism / Q000187:drug effects*; D005947:Glucose / Q000378:metabolism; D007425:Intracellular Membranes / Q000378:metabolism; D019344:Lactic Acid / Q000096:biosynthesis; D008833:Microcirculation; D051381:Rats; D013778:Tetrazolium Salts / Q000378:metabolism; D013844:Thiazoles / Q000378:metabolism
D000199:Actins; D002951:Citrates; D013778:Tetrazolium Salts; D013844:Thiazoles; D019344:Lactic Acid; C007744:fluorocitrate; D000255:Adenosine Triphosphate; C022616:thiazolyl blue; D005947:Glucose